REG - Abingdon Health PLC - Salistick™ to be launched in Germany

Abingdon HealthAnnouncement

17/03/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250317:nRSQ8079Aa&default-theme=true

RNS Number : 8079A  Abingdon Health PLC  17 March 2025

 

Abingdon Health plc

("Abingdon Health" or "the Company")

 

Salistick (https://www.salignostics.com/salistick/) ™ to be launched in
Germany with leading retailers

Initial purchase order for 70,000 tests received

 

York, U.K. 17 March  2025: Abingdon Health plc (AIM: ABDX), a leading
international developer, manufacturer and distributor of high quality and
effective rapid tests, announces the extension of its distribution agreement
with Salignostics (https://www.salignostics.com/) , for the launch of an
own-brand version of Salistick (https://www.salignostics.com/salistick/) ™
(https://www.salignostics.com/salistick/) , the first saliva-based pregnancy
test, in a number of European territories including Germany, Poland and
Austria.

 

After successfully launching Salistick™ in the United Kingdom, where it is
now available at Superdrug, Tesco, Amazon, and under the Boots own brand
range, Abingdon Health has extended its distribution agreement with
Salignostics to a number of key European markets, including the German market
on an exclusive basis. Abingdon Health, along with its long-standing
distribution partner NeutraPharma (https://neutrapharma.com/) , expects to
launch an own-branded version Salistick™ with major German retailers,
including DM, Rossman and Mueller, in calendar year Q2 2025.

 

Abingdon Health has received an initial purchase order for 70,000 tests, with
further purchase orders anticipated during the calendar year 2025 on a
quarterly basis.

 

Salistick™ is a rapid saliva-based pregnancy test that offers women a new
and improved user-experience, and high accuracy for early pregnancy detection.
Salistick™ is based on Salignostics' revolutionary technology which detects
the pregnancy hormone β-hCG in saliva. Traditional pregnancy tests are
urine-based and Salistick™ offers the ability to test anywhere, at any time.

 

 

 

Salignostics Ltd is an Israeli company that since 2016 has been developing
cutting-edge technologies which transform saliva into a reliable body-fluid
for lateral flow immunoassays like this hCG Pregnancy Rapid Test. The
ingenuity of this technology lies in the ability to overcome physiological
obstacles found in the chemical, biological and physical features of saliva.
Salignostics' method provides a revolutionary technological platform for
saliva diagnostics across a wide range of possible uses.

 

The Abingdon Simply Test range, including Salistick™
(https://www.salignostics.com/salistick/) , now includes over 16 self-tests
which are sold direct-to-consumer through the Abingdon Simply Test
(http://www.abingdonsimplytest.com) website and through own brand and private
label distribution partners in Europe. Abingdon Health will continue to expand
its range of innovative self-tests that are available to consumers through
partnering with innovative companies such as Salignostics to offer the very
best in novel self-test technology to the market.

 

Chris Yates, CEO of Abingdon Health plc, commented: "We are incredibly proud
and excited to be launching Salistick™, the first saliva pregnancy test, in
Germany and other European territories following on from our successful
commercial roll-out in the UK. This exciting innovation offers the opportunity
to test for pregnancy anytime, anywhere. We are delighted to extend our
partnerships with Salignostics and NeutraPharma and we look forward to
continuing to work with them to bring further innovative self-test products to
market."

 

Dr. Guy Krief Co-founder and Deputy CEO at Salignostics, commented: "We are
excited to join with Abingdon Health and NeutraPharma to bring our
Salistick saliva-based pregnancy test to consumers in major European
territories including Germany. We believe these partnerships provide us the
platform to bring this revolutionary product to pharmacy shelves throughout
the region, allowing for easy and accessible pregnancy tests."

 

Enquiries

 

 Abingdon Health plc                                                             www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Yates, Chief Executive Officer                                            Via Walbrook PR
 Chris Hand, Executive Chairman

 Zeus Capital (Sole Broker and Nominated Adviser)                                  Tel: +44 (0) 20 3829 5000
 Antonio Bossi / Alexandra Campbell-Harris (Corporate Finance)
 Fraser Marshall (Corporate Broking)

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                               (mailto:abingdon@walbrookpr.com)
 Paul McManus / Alice Woodings                 Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654
 Phillip Marriage                              +44 (0)7867 984 082

 

 

About Abingdon Health plc

Abingdon Health is a leading med-tech contract service provider offering its
services to an international customer base.

 

The Group's CDMO division (https://www.abingdonhealth.com/services/) offers
lateral flow product development, regulatory support, technology transfer and
manufacturing services for customers looking to develop new assays or transfer
existing laboratory-based assays to a lateral flow format. Abingdon Health's
CDMO division has the internal capabilities to take lateral flow projects, in
areas such as infectious disease and clinical testing, including companion
diagnostics, animal health and environmental testing, from initial concept
through to routine and large-scale manufacturing; from "idea to commercial
success".

 

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences)
(https://cslifesciences.com) and IVDeology (https://www.ivdeology.co.uk) ,
provide a broad range of regulatory services to the in vitro diagnostic and
wider medical device industry, to support customers in bringing products to
market across a range of territories including the USA, EU and the UK. Our
consultancy services range from design, implementation and maintenance of
quality management systems, preparation of technical files for regulatory
approvals, part-time and interim management support, auditing both internally
(e.g. Quality Management Systems) and externally (e.g. critical suppliers),
management reviews and presentations, training and mentoring.

 

Abingdon Health's Abingdon Simply Test range of self-tests is an e-commerce
platform that offers a range of self-tests to empowers consumers to manage
their own health and wellbeing. The Abingdon Simply Test
(http://www.abingdonsimplytest.com) e-commerce site offers consumers a range
of information to support them in making informed decisions on the tests
available. In addition, the site provides Abingdon's contract services
customers with a potential route to market for self-tests. The Abingdon Simply
Test range and other selected self-test products, such as the saliva pregnancy
test, Salistick (https://www.salignostics.com/salistick/) (TM
(https://www.salignostics.com/salistick/) ), is also sold through
international distributors and through other channels in the UK and Ireland,
such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England with
CDMO facilities in both York, UK and Madison, Wisconsin, USA. For more
information visit: www.abingdonhealth.com (http://www.abingdonhealth.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQZLFFEXLEBBZ